Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Simona Casalino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0895-6387; OpenAlex author ID A5015782900, A5103933067. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: 1 paper · 2026: 6 papers

Papers 16

  1. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Co-author DOI 10.1016/j.ejca.2026.116683↗
  2. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Co-author DOI 10.1016/j.esmoop.2026.106964↗
  3. CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102900↗
  4. EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages. Co-author DOI 10.1038/s41388-026-03774-0↗
  5. Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-026-01442-w↗
  6. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  7. Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.esmogo.2025.100179↗
  8. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.05.547↗
  9. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  10. CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Co-author DOI 10.1038/s41698-024-00742-3↗
  11. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-0104↗
  12. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. First author DOI 10.1177/17588359241234487↗
  13. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  14. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Co-author DOI 10.3389/fsurg.2022.866173↗
  15. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  16. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers12051131↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davide Melisi · 16 shared papers, 2020–2026 · strength 3.29
  2. Valeria Merz · 11 shared papers, 2020–2026 · strength 2.01
  3. Silvia Pietrobono · 9 shared papers, 2022–2026 · strength 1.96
  4. Enza Scarlato · 6 shared papers, 2024–2026 · strength 1.41
  5. Giovanni Butturini · 4 shared papers, 2020–2026 · strength 0.73
  6. Giuseppe Malleo · 3 shared papers, 2020–2026 · strength 0.51
  7. Mirko D’Onofrio · 3 shared papers, 2020–2026 · strength 0.51
  8. Roberto Salvia · 3 shared papers, 2020–2026 · strength 0.48
  9. Riccardo De Robertis Lombardi · 2 shared papers, 2024–2026 · strength 0.44
  10. Mario Scartozzi · 2 shared papers, 2023–2026 · strength 0.33
  11. Letizia Procaccio · 2 shared papers, 2023–2026 · strength 0.33
  12. Andrea Pretta · 2 shared papers, 2023–2026 · strength 0.33
  13. Elisa Giommoni · 2 shared papers, 2023–2026 · strength 0.33
  14. Sara Lonardi · 2 shared papers, 2023–2026 · strength 0.33
  15. Ferdinando De Vita · 2 shared papers, 2023–2026 · strength 0.33
  16. Francesca Bergamo · 2 shared papers, 2023–2026 · strength 0.33
  17. Guido Giordano · 2 shared papers, 2023–2026 · strength 0.33
  18. Alberto Zaniboni · 2 shared papers, 2023–2026 · strength 0.33
  19. Michèle Milella · 3 shared papers, 2020–2023 · strength 0.32
  20. Flavio Spoto · 1 shared paper, 2026 · strength 0.29
  21. Johanna W. Wilmink · 1 shared paper, 2026 · strength 0.27
  22. Esther N. Pijnappel · 1 shared paper, 2026 · strength 0.27
  23. Judith de Vos‐Geelen · 1 shared paper, 2026 · strength 0.27
  24. Anne M. Gehrels · 1 shared paper, 2026 · strength 0.27
  25. Gerald W. Prager · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.